Literature DB >> 25210032

Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.

Awet Tecleab1, Xiaolei Zhang2, Said M Sebti3.   

Abstract

Ral GTPases are critical effectors of Ras, yet the molecular mechanism by which they induce malignant transformation is not well understood. In this study, we found the expression of K-Ras, RalB, and sometimes RalA, but not AKT1/2 and c-Raf, to be required for maintaining low levels of p53 in human cancer cells that harbor mutant K-Ras and wild-type p53. Down-regulation of K-Ras, RalB, and sometimes RalA increases p53 protein levels and results in a p53-dependent up-regulation of the expression of p21(WAF). K-Ras, RalA, and RalB depletion increases p53 stability as demonstrated by ataxia telangiectasia-mutated kinase activation, increased Ser-15 phosphorylation, and a significant (up to 6-fold) increase in p53 half-life. Furthermore, depletion of K-Ras and RalB inhibits anchorage-independent growth and invasion and interferes with cell cycle progression in a p53-dependent manner. Depletion of RalA inhibits invasion in a p53-dependent manner. Thus, expression of K-Ras and RalB and possibly RalA proteins is critical for maintaining low levels of p53, and down-regulation of these GTPases reactivates p53 by significantly enhancing its stability, and this contributes to suppression of malignant transformation.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Apoptosis; Cancer Biology; K-Ras; RalA; RalB; Ras Protein; Serine 15 Phosphorylation; Signal Transduction; p53

Mesh:

Substances:

Year:  2014        PMID: 25210032      PMCID: PMC4223330          DOI: 10.1074/jbc.M114.565796

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Akt enhances Mdm2-mediated ubiquitination and degradation of p53.

Authors:  Yoko Ogawara; Shohei Kishishita; Toshiyuki Obata; Yuko Isazawa; Toshiaki Suzuki; Keiji Tanaka; Norihisa Masuyama; Yukiko Gotoh
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

2.  RalA but not RalB enhances polarized delivery of membrane proteins to the basolateral surface of epithelial cells.

Authors:  Michail Shipitsin; Larry A Feig
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

3.  Species- and cell type-specific requirements for cellular transformation.

Authors:  Annapoorni Rangarajan; Sue J Hong; Annie Gifford; Robert A Weinberg
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

4.  Oncogenic ras and p53 cooperate to induce cellular senescence.

Authors:  Gerardo Ferbeyre; Elisa de Stanchina; Athena W Lin; Emmanuelle Querido; Mila E McCurrach; Gregory J Hannon; Scott W Lowe
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

5.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

6.  RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival.

Authors:  Yuchen Chien; Michael A White
Journal:  EMBO Rep       Date:  2003-07-11       Impact factor: 8.807

Review 7.  Distinct requirements for Ras oncogenesis in human versus mouse cells.

Authors:  Nesrin M Hamad; Joel H Elconin; Antoine E Karnoub; Wenli Bai; Jeremy N Rich; Robert T Abraham; Channing J Der; Christopher M Counter
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

8.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

9.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.

Authors:  Carmen Guerra; Nieves Mijimolle; Alma Dhawahir; Pierre Dubus; Marta Barradas; Manuel Serrano; Victoria Campuzano; Mariano Barbacid
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  12 in total

1.  Brusatol overcomes chemoresistance through inhibition of protein translation.

Authors:  Bryan Harder; Wang Tian; James J La Clair; Aik-Choon Tan; Aikseng Ooi; Eli Chapman; Donna D Zhang
Journal:  Mol Carcinog       Date:  2017-02-08       Impact factor: 4.784

2.  The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.

Authors:  Hua Yang; Shengyan Xiang; Aslamuzzaman Kazi; Said M Sebti
Journal:  J Biol Chem       Date:  2020-01-30       Impact factor: 5.157

3.  SIRT2 and Lysine Fatty Acylation Regulate the Activity of RalB and Cell Migration.

Authors:  Nicole A Spiegelman; Xiaoyu Zhang; Hui Jing; Ji Cao; Ilana B Kotliar; Pornpun Aramsangtienchai; Miao Wang; Zhen Tong; Kelly M Rosch; Hening Lin
Journal:  ACS Chem Biol       Date:  2019-09-03       Impact factor: 5.100

4.  Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer.

Authors:  Nannan Feng; Travers Ching; Yu Wang; Ben Liu; Hongyan Lin; Oumin Shi; Xiaohong Zhang; Min Zheng; Xin Zheng; Ming Gao; Zhi-Jie Zheng; Herbert Yu; Lana Garmire; Biyun Qian
Journal:  Sci Rep       Date:  2016-11-16       Impact factor: 4.379

5.  Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.

Authors:  Andrea Orue; Valery Chavez; Mary Strasberg-Rieber; Manuel Rieber
Journal:  BMC Cancer       Date:  2016-11-18       Impact factor: 4.430

Review 6.  Ral signaling pathway in health and cancer.

Authors:  Adel Rezaei Moghadam; Elham Patrad; Elham Tafsiri; Warner Peng; Benjamin Fangman; Timothy J Pluard; Anthony Accurso; Michael Salacz; Kushal Shah; Brandon Ricke; Danse Bi; Kyle Kimura; Leland Graves; Marzieh Khajoie Najad; Roya Dolatkhah; Zohreh Sanaat; Mina Yazdi; Naeimeh Tavakolinia; Mohammad Mazani; Mojtaba Amani; Saeid Ghavami; Robyn Gartell; Colleen Reilly; Zaid Naima; Tuba Esfandyari; Faris Farassati
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

7.  A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.

Authors:  Ellen Siebring-van Olst; Maxime Blijlevens; Renee X de Menezes; Ida H van der Meulen-Muileman; Egbert F Smit; Victor W van Beusechem
Journal:  Mol Oncol       Date:  2017-04-11       Impact factor: 6.603

8.  Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma.

Authors:  Jiejie Qin; Shuaibing Wang; Jianxiang Shi; Yan Ma; Keyan Wang; Hua Ye; Xiaojun Zhang; Peng Wang; Xiao Wang; Chunhua Song; Liping Dai; Kaijuan Wang; Binghua Jiang; Jianying Zhang
Journal:  Cancer Sci       Date:  2019-05-07       Impact factor: 6.716

9.  Ral GTPase is essential for actin dynamics and Golgi apparatus distribution in mouse oocyte maturation.

Authors:  Ming-Hong Sun; Lin-Lin Hu; Chao-Ying Zhao; Xiang Lu; Yan-Ping Ren; Jun-Li Wang; Xiang-Shun Cui; Shao-Chen Sun
Journal:  Cell Div       Date:  2021-06-10       Impact factor: 5.130

10.  RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.

Authors:  Hajrah Khawaja; Andrew Campbell; Jamie Z Roberts; Arman Javadi; Paul O'Reilly; Darragh McArt; Wendy L Allen; Joanna Majkut; Markus Rehm; Alberto Bardelli; Federica Di Nicolantonio; Christopher J Scott; Richard Kennedy; Nicolas Vitale; Timothy Harrison; Owen J Sansom; Daniel B Longley; Emma Evergren; Sandra Van Schaeybroeck
Journal:  Cell Death Dis       Date:  2020-10-29       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.